Pharmaceutical - Pharmaceutical, CSL Limited

Filter

Current filters:

PharmaceuticalCSL Limited

Popular Filters

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Report: IPOs and government support can boost the Australian life sciences industry

Report: IPOs and government support can boost the Australian life sciences industry

18-02-2014

Despite a relatively flat December quarter for the PricewaterhouseCoopers Life Sciences Index, it was…

AustraliaBiotechnologyCSL LimitedFinancialMarkets & MarketingPharmaceutical

Australia’s CSL posts solid half-year results

Australia’s CSL posts solid half-year results

13-02-2014

Australian blood products and vaccine maker CSL reported a 3% rise in net profit to $646 million (all…

CSL LimitedFinancialHematologyPharmaceuticalVaccines

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

08-12-2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the…

BayerCardio-vascularCSL BehringCSL LimitedEuropeHelixateHematologyKogenatePharmaceuticalRegulation

CSL presents positive data for potential new heart attack therapy

28-11-2013

Australian blood products and vaccine maker CSL says results of a Phase IIa trial of CSL112 in patients…

Cardio-vascularCSL LimitedCSL112PharmaceuticalResearch

CSL settles US antitrust class action litigation

CSL settles US antitrust class action litigation

09-10-2013

Australian blood products and vaccine maker CSL has signed an agreement to settle the US antitrust class…

CSL LimitedFinancialHematologyLegalNorth AmericaPharmaceutical

CSL Behring's rIX-FP shows efficacy in severe hemophilia B

03-07-2013

Data presented by CSL Behring today (July 3) showed clinical efficacy of a once-weekly dosing regimen…

CSL BehringCSL LimitedPharmaceuticalResearch

FDA approves CSL's Kcentra and accepts Octapharma Octaplex BLA for reversal of anticoagulation

30-04-2013

The US Food and Drug Administration has approved Kcentra (prothrombin complex concentrate, human) from…

BiotechnologyCardio-vascularCSL BehringCSL LimitedKcentraNorth AmericaOctapharmaOctaplexPharmaceuticalRegulation

CSL Behring gains expanded use for Corifact in USA

06-03-2013

Corifact, Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding…

CorifactCSL BehringCSL LimitedNorth AmericaPharmaceuticalRare diseasesRegulation

Animal models show CSL drug candidate is research breakthrough in diabetes

28-09-2012

Australia's CSL Limited (ASX: CSL) has developed a new drug candidate - dubbed 2H10 - that is able to…

2H10CSL LimitedDiabetesPharmaceuticalResearch

CSL Biotherapies gets US government contract for flu vaccines

11-09-2012

CSL Biotherapies, a US subsidiary of Australia's CSL (ASX: CSL), one of the world's leading manufacturers…

CSL BiotherapiesCSL LimitedFinancialNorth AmericaPharmaceuticalProductionVaccines

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top